The marine biodiscovery pipeline and ocean medicines of tomorrow by Crawford, Alexander Dettmar et al.
The marine biodiscovery pipeline and ocean
medicines of tomorrow
marcel jaspars1, donatella de pascale2, jeanette h. andersen3, fernando reyes4,
alexander d. crawford5 and adrianna ianora6
1Department of Chemistry, Marine Biodiscovery Centre, University of Aberdeen, Aberdeen AB24 3UE, Scotland, UK, 2Institute of
Protein Biochemistry, National Research Council, Via Pietro Castellino, 111, I-80131 Naples, Italy, 3University of Tromsø,
Forskningsparken FPARK A 203, Tromsø, Norway, 4Fundacio´n MEDINA, Parque Tecnolo´gico de Ciencias de la Salud, Av. del
Conocimiento 34, 18016 Armilla, Granada, Spain, 5Laboratory for Molecular Biodiscovery, University of Leuven, Herestraat 49, 3000
Leuven, Belgium, 6Stazione Zoologica Anton Dohrn, Villa Comunale 80121, Naples, Italy
Marine organisms possess the capacity to produce a variety of unique and biologically potent natural products for treating
human diseases, many of which are currently commercially available or are in advanced clinical trials. Here we provide a
short review on progress in the ﬁeld and discuss a case study of an EU-funded project, PharmaSea, which aims to discover
novel products for the treatment of infections, inﬂammation and neurodegenerative diseases. Research in this sector is
opening new doors for harnessing the potential of marine natural products with pharmaceutical properties.
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I NTRODUCT ION
A signiﬁcant portion of the Earth’s biodiversity (an estimated
25% of the total number of species on Earth) is comprised of
marine species (Mora et al., 2011). These have evolved
mechanisms to survive in an extremely different and hostile
environment compared with land in terms of light, salinity
and pressure. This is reﬂected by the myriad of secondary
metabolites (or natural products) that they produce to
defend themselves against predators, to locate mates and to
out-compete competitors for limited resources. Many of
these compounds have no terrestrial analogues and are
unique in terms of chemical structure and biological activity.
What makes these products interesting for humans are their
potential applications as pharmaceuticals for the treatment
of numerous diseases or as templates for medicinal chemistry.
Humans have been trying to understand and use ocean
resources for medicinal purposes since ancient times. The
Chinese and Japanese were eating a variety of iodine-rich sea-
weeds already in 1400 BC that accounted for their low inci-
dence of goitre (Leoutsakos, 2004). In Ireland, the red algae
Chondrus crispus and Mastocarpus stellatus were used as a
folk cure for colds, sore throats, chest infections and bron-
chitis for several centuries (Dias et al., 2012). In the early
20th century cod liver oil was an important nutritional supple-
ment in many northern European countries. However it was
only after the 1950s, with the advent of scuba diving and
new sampling technologies that scientists began to systematic-
ally probe the oceans for useful therapeutics. The number of
potential compounds isolated from marine organisms now
exceeds 28,000 with hundreds of new compounds being dis-
covered every year (Blunt et al., 2015). However, despite the
number of compounds isolated from marine organisms and
the biological activities attributed to many of these, those
that have either been marketed or are under development
are relatively few.
There are several reasons for this including the time and
cost it takes to reach the market, difﬁculties in harvesting
the organism, low titres of natural product in producing
organisms, difﬁculties in isolation and puriﬁcation proce-
dures, problems in obtaining a sustainable supply of the com-
pound, high toxicity of the active compound, ecological
impact on natural populations, and insufﬁcient investment
by pharmaceutical companies (Torjesen, 2015). However, not-
withstanding these difﬁculties there has been a ‘renaissance’ in
marine drug discovery in the last decade due to technological
developments that have accelerated structural elucidation and
screening, and the use of marine microbial genomics to
provide biosynthetic pathways for the production of marine
natural products (Glaser and Mayer, 2009). The development
of emerging ‘omics’ tools such direct sequencing of eDNA,
next generation sequencing technologies, metaproteomic
and synthetic biology, heterologous expression and bioinfor-
matic tools will improve the discovery and production of
these compounds and facilitate the study of biosynthetic path-
ways of organisms previously inaccessible by traditional
methods (see review by Rocha-Martin et al., 2014). This is
coupled with the fact that alternative technologies such as
combinatorial chemistry have failed to provide the pharma-
ceutical industry with the chemical diversity necessary to sig-
niﬁcantly increase the number of new drug-like leads.
Here we discuss the current state of art of marine com-
pounds approved, developed or in clinical trials for treating
various diseases, or marketed as nutraceuticals and cosmeceu-
ticals. Several excellent reviews already exist on marine drug
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discovery so this paper does not attempt to provide a compre-
hensive overview, but rather to illustrate some examples of the
recent advances in this ﬁeld. We also discuss the ambitions and
efforts of an on-going EU project to ﬁnd new molecules from
microorganisms for the treatment of bacterial and viral infec-
tions, and inﬂammatory and neurodegenerative diseases.
With a focus on under-exploited marine phyla of cultivable
microorganisms, essentially photo- and chemosynthetic bac-
teria together with fungi and microalgae, this project aims to
achieve optimized and sustainable production of relevant
biomass and high added-value compounds for pharmaceutical,
nutraceutical and cosmeceutical applications, and to overcome
some of the major bottlenecks in the drug discovery pipeline.
MAR INE DRUGS IN CL IN I CAL USE
Marine-derived compounds are more bioactive than those of
terrestrial origin, especially in terms of cytotoxicity. It is no
surprise, therefore, that marine natural products have their
stronghold in the area of anticancer chemotherapy, as indi-
cated by the list of compounds that have already made it to
the market or are currently under clinical investigation. To
date, the global marine pharmaceutical pipeline consists of
seven approved pharmaceuticals in clinical use, four of
which are anticancer drugs (Figure 1). The ﬁrst marine-
derived anticancer agent to be developed for clinical use,
cytarabine or Ara-C, is a synthetic analogue of a
C-nucleoside from the Caribbean sponge, Cryptothethya
crypta, approved in 1969 and still in use today to treat acute
myelocytic leukaemia and non-Hodgkin’s lymphoma (Sagar
et al., 2010). Almost 20 years later in 2007 the next anticancer
agent from the tunicate Ecteinascidia turbinata would be
approved, trabectedin (Yondelis), for the treatment of soft
tissue sarcomas and ovarian cancer (Schoffski et al., 2008).
A third marine anticancer success story was the discovery of
the polyether metabolite halichondrin A from the sponge
Halichondria okadai (Hirata & Uemura, 1986). A simpler
structure containing the pharmacophore obtained synthetical-
ly gave rise to Eribulin (Halaven), the most complex synthetic
drug ever made, approved for the treatment of drug refractory
breast cancer in 2010 (Menis & Twelves, 2011). The most
recently approved anticancer compound from the marine
environment is brentuximab vedotin (Adcetris), a chimeric
antibody attached through a protease-cleavable linker to a
derivative of the potent antitubulin agent dolastatin 10 (Katz
et al., 2011) used for the treatment of Hodgkin’s lymphoma
and anaplastic large cell lymphoma.
Marine natural products have also found applications as
antiviral drugs used to treat herpes simplex infections.
Vidarabine or Ara-A is a synthetic analogue of spongouridine
with improved antiviral activity, originally isolated in 1950
from the sponge Tethya crypta (Sagar et al., 2010), but cur-
rently obtained from fermentation cultures of the bacterium
Streptomyces antibioticus. Another important marine natural
product, ziconotide (commercial name Prialt; Klotz, 2006),
is a synthetic calcium-channel binding conotoxin from
Conus magus, the Magician’s cone snail, which has proved
effective in patients with intractable severe pain who either
do not respond to or cannot tolerate other drugs. Additional
conotoxins are in clinical development with potential applica-
tions in pain management and are widely employed tool com-
pounds in neurotoxin research (Daly & Craik, 2011). Finally,
marine products obtained from ﬁsh oils, typically from oily
ﬁsh such as mackerel and anchovy, have found applications
as a lipid-regulating agent (commercial name Lovaza) to
reduce severe elevations of triglycerides associated with condi-
tions such as obesity, insulin resistance, diabetes mellitus and
other factors that contribute to the risk of atherosclerosis or
hardening of the arteries responsible for coronary artery
disease. According to Gerwick & Moore (2012) the current
success rate of discovery from the marine world, namely
seven clinically useful and approved drugs from 28,175 dis-
covered molecular entities (e.g. one drug per 4025 natural pro-
ducts described) is approximately 1.2- to 2.5-fold better than
the industry average (1 in 5000–10,000 tested compounds)
(http://www.pharma.org/sites/default/ﬁles/159/rd_bro-
chure_022307.pdf).
NEW DRUGS IN DEVELOPMENT
Currently there are about 26 natural products in Phase I to
Phase III clinical trials, 23 as anticancer cancer agents, two
for schizophrenia and Alzheimer’s, and one for chronic pain
(http://marinepharmacology.midwestern.edu/clinPipeline.htm).
Thus, the pipeline of promising marine derived compounds is
very strong, and several of these agents are likely to reach the
market in the coming years (Mayer et al., 2010). Some of
these new marine drugs are discussed brieﬂy in the next section.
Anticancer
Aplidine (dehydrodidemnin B), a depsipeptide dehydrodi-
demnin isolated from the Mediterranean tunicate Aplidium
albicans has antiproliferative activity by blocking the cell
cycle and inducing apoptosis, with strong activity against mul-
tiple myeloma cells. PharmaMar is currently developing
Aplidin for the treatment of multiple myeloma (phase III of
clinical trials), and for solid and haematological malignant
neoplasias, like T-cell lymphoma (phase II of clinical trials)
(http://www.pharmamar.com/aplidin.aspx).
Plinabulin is a synthetic analogue of a natural product iso-
lated from a marine fungus (Aspergillus sp.) that inhibits
tubulin polymerization, leading to the disruption of the vascu-
lar endothelial architecture of the tumour. BeyondSpring
Pharmaceuticals is developing plinabulin and announced the
start of phase III clinical trials in patients with non-small
cell lung cancer in 2015 (http://www.beyondspringpharma.
com/press-release-plinabulin-phase-3-trial/).
Salinosporamide A (Marizomib; Potts et al., 2011) is a
novel, potent proteasome inhibitor from the marine actino-
mycete, Salinispora tropica, that induces apoptosis by a
caspase-8 dependent mechanism in multiple myeloma and
leukaemia cells. Currently, combination therapies of salinos-
poramide A with other drugs are under investigation in
phase I clinical trials.
Further examples of anticancer drugs of marine origin in
clinical development are discussed by Newman and Cragg
(Newman & Cragg, 2014).
Alzheimer’s disease
Bryostatin 1, a macrolide lactone isolated from the bryozoan
species, Bugula neritina, is a potent modulator of protein
kinase C that is currently in phase II clinical trials for the
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treatment of Alzheimer’s disease by Neurotrope Bioscience
(http://www.neurotropebioscience.com/). The drug has shown
pre-clinical efﬁcacy to not only treat Alzheimer’s disease symp-
toms, but also its underlying causes. Bryostatin was originally
intended for anti-cancer chemotherapy, butwas then discovered
to potentially arrest Alzheimer’s disease (Lorente et al., 2014).
Pre-clinical testing revealed that it reduced the toxic
Alzheimer’s disease protein amyloid-b and the deposits of
amyloid-b called amyloid plaques, restored lost synapses, and
protected against the loss of memory functions.
DMXBA, a synthetic analogue of the toxic alkaloid pro-
duced by several nemertinean worm species, such as
Paranemertes peregrine and Amphiporus lactiﬂoreus, improves
cognition and sensory deﬁcit in several animal models, and
has shown neuroprotective effects in vitro and in vivo (Rangel
& Falkenberg, 2015). Phase I and II clinical trials showed a sig-
niﬁcant cognitive improvement in healthy young adults and in
schizophrenic patients (Rangel & Falkenberg, 2015). Comentis
Inc. is developing the drug for treatment for Alzheimer’s disease
and schizophrenia (http://comentis.com/).
Analgesics
The guanidine alkaloid tetrodotoxin (TTX), a blocker of voltage
dependent sodium channels isolated from ﬁsh, algae and bac-
teria, has shown therapeutic efﬁcacy as an analgesic in cancer
patients. Two formulations are currently under evaluation in
phases II and III of clinical trials by the Canadian WEX
Pharmaceuticals Inc.: the ﬁrst formulation is in phase III, indi-
cated for the treatment of neuropathic pain in cancer patients;
the second one is in phase II of clinical trials, for peripheral
pain and cancer-related pain (http://www.wextech.ca/clinical_
trials.asp?m=1&s=0&p=0; http://www.clinicaltrials.gov).
Antibacterials
Despite the urgent need for new antibiotics, particularly to
tackle the rise of antibiotic-resistant bacteria, new antibiotic
development has moved slowly and there are few compounds
in the antibiotic development pipeline. This lack of activity
reﬂects market failure as the risk–reward ratio has been con-
sidered unattractive for pharmaceutical companies. Mayer
et al. (2013) lists 23 antibacterial compounds in preclinical
pharmacological research. An interesting example is
Anthracimycin, a polyketide antibiotic discovered in 2013,
derived from marine actinobacteria that has shown signiﬁcant
activity against Bacillus anthracis, the bacteria that causes
anthrax (Jang et al., 2013).
MAR INE NUTRACEUT ICALS AND
COSMECEUT ICALS
Currently there is also great interest in marine-derived pro-
ducts as nutraceuticals and cosmeceuticals because of their
beneﬁcial effects on human health. These often have drug-like
properties (hence the term -ceutical) and contain active ingre-
dients such as vitamins, phytochemicals, enzymes, antioxi-
dants and essential oils which are ﬁnding uses as natural
additives in foods, as nutritional supplements including
colour additives and antioxidants, and as vitamins, oils and
cofactors which enhance general well-being. Compared with
Fig. 1. Pharmaceutical drugs in commercial use.
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high-value pharmaceuticals, these medium-value products
have a rapid route to market and many companies have
chosen to go along the functional product route as it offers
lower risk and a quicker potential return on investment
than the high-risk high-reward pharmaceutical market.
The main products of primary interest for marine nutraceu-
ticals include omega-3 ﬁsh/algal oil, phospholipids (bound
omega 3-fatty acids), micro/macro algal nutrition supplements,
ﬁsh proteins and peptides, hydrolysates, shellﬁsh chitin, ﬁsh col-
lagen and mineral supplements (Figure 2). Polyunsaturated
v23 fatty acids are purported to have a range of beneﬁcial
effects including improved heart health and reduced inﬂamma-
tion. Several population studies report that dietary v23 fatty
acids or ﬁsh oil may also reduce the risk of developing breast,
colon or prostate cancer. In addition to the traditional sources
of the v23-ﬁsh oils, krill oil has also become very popular.
This oil is different from the traditional ﬁsh oils because it con-
tains three active components: v23 fatty acids, phospholipids
and the carotenoid astaxanthin, a potent antioxidant. Marine
microalgae are also rich in v23 oils. Made from various
species of microalgae, this new omega-3 oil is reported to
contain the same lipid type as ﬁsh oil, triglycerides. The advan-
tage in this case is that production from this source is more eco-
sustainable and less damaging to the environment than produc-
tion of ﬁsh and krill oils.
Current nutraceutical markets from marine organisms are
also focused on chemicals such as carotenoids due to their
high market value, projected to reach E 1.27 billion by 2019
(http://www.marketsandmarkets.com/PressReleases/carotenoid.
asp). Carotenoids have much potential as food colourants, feed
supplements, nutraceuticals, and for cosmetic and pharmaceut-
ical purposes. There are well over 600 known carotenoids, with
beta-carotene, alpha-carotene, lutein, zeaxanthin, lycopene,
fucoxanthin and astaxanthin being the most common.
Astaxanthin is one of the better known in terms of its status as
a ‘supernutrient,’ as it is the only one to easily cross the
blood–brain barrier and other bio-membranes which makes it
more easily absorbed and transported to all tissues and organs
in the body. Research suggests that astaxanthin is an optimum
ingredient choice for eye protection, skin health, anti-ageing,
anti-fatigue or any conditionwhere protection from free radicals
is needed (Fiedor & Burda, 2014).
Another carotenoid, fucoxanthin,may play a role in reducing
obesity (Gammone & D’Orazio, 2015). So far, only animal
studies have been conducted but these show that fucoxanthin,
found in edible brown seaweed and microalgae such as the
diatoms Phaeodactylum tricornutum or Cylindrotheca closter-
ium, promotes the loss of abdominal fat in obese mice and
rats. Although it is not fully understood how fucoxanthin
works, it appears to target protein UCP1 that increases the
rate at which abdominal fat is burned. Fucoxanthin has also
been found in animal studies to decrease insulin and blood
glucose levels. Researchers hypothesize that fucoxanthin may
have anti-diabetes effects because it stimulates the formation
of v23 fatty acids which are thought to increase insulin sensi-
tivity, improve triglycerides and reduce LDL (‘bad’) cholesterol.
Fig. 2. Marine nutraceuticals and their health beneﬁts.
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Together with the pharmaceutical and nutraceutical indus-
tries, the cosmeceutical industry is increasingly turning to the
sea in the search for new molecules. One of the most common
molecular classes of compounds used in the personal care bio-
active ingredients sector is the exopolysaccharides (EPS).
Various microorganisms produce EPS, including proteobac-
teria, cyanobacteria and archaea. Abyssine by Lucas Meyers
is an Alteromonas ferment extract containing the EPS
HYD657, named deepsane, produced and secreted by the
strain Alteromonas macleodii subsp. ﬁjiensis biovar deepsane
(Cambon-Bonavita et al., 2002). Deepsane is commercially
available under the name of Abyssine for soothing and redu-
cing irritation of sensitive skin against chemical, mechanical
and ultraviolet B aggression (Martins et al., 2014). A
ferment of the deep sea hydrothermal vent bacterium
Thermus thermophilus (Venuceane
TM
produced by Sederma
Cosmetics) is a potent antioxidant that inhibits damage
from reactive oxygen species, protects natural defence
enzymes, shields from UV damage, and restores barrier lipids.
Resilience is a line of skincare products from the Este´e
Lauder Company that contains a special extracellular extract
from the Caribbean Sea whip (gorgonian) Pseudopterogorgia
elisabethae. This extract is mainly composed by pseudoptero-
sins, which are potent anti-inﬂammatory and analgesic agents
that inhibit eicosanoid biosynthesis by inhibition of both
phospholipase A2 and 5-lipoxygenase. Additionally, a deriva-
tive of a natural pseudopterosin, methopterosin, has com-
pleted phase I and II clinical trials as a wound-healing agent.
Microalgae are the source of some of the most innovative
skincare products today. Some examples include
Dermochlorella DG, XCELL-30, Alguronic Acid and Alguard.
Dermochlorella DG from CODIF Recherche et Nature
(Brittany, France) is a Chlorella sp. extract containing oligopep-
tides that increases ﬁrmness and skin tone. XCELL-30 from
Greensea (Me`ze, France) is developed from microalgae
endemic to Madagascar, and speciﬁcally acts on cellular turn-
over in the basal layer of the epidermis, thus allowing the pres-
ervation of the youthful characteristics of the skin. Alguronic
Acid from Algenist (San Francisco, CA, USA) is an undeter-
mined mix of polysaccharides produced bymicroalgae with sig-
niﬁcant anti-ageing properties, helping to rejuvenate the skin
for a more youthful appearance. Alguard is a natural sulphated
polysaccharide compound isolated from a single red microalga
(Porphyridium sp.) that protects against photo damage, ageing
and micro-abrasion of the skin.
PHARMASEA : A CASE STUDY OF A
DRUG D ISCOVERY PROJECT
Marine natural products constitute a strategic research area
with potentially enormous economic and social revenues.
According to EuroOcean (http://www.eurocean.org/np4/
2502.html) there are over 590 European marine projects
that have been funded under both FP6 and FP7 programmes
(see also Martins et al., 2014), which shows the engagement of
academia and industry in bringing more marine bioactives
into the market.
An example is the EU PharmaSea project, an
SME-academia-driven project initiated by 24 partners in 2012
to discover novel products for the treatment of bacterial infec-
tions, inﬂammation and neurodegenerative conditions such as
Alzheimer’s disease. The novelty of the project is that it searches
for new microbial biodiversity to treat these diseases in some of
the deepest, coldest and hottest places on the planet. By choos-
ing deep and cold marine environments scientists hope to tap
novel diversity not seen before. Deep ocean trenches are
islands of diversity in which evolution may have progressed dif-
ferently. The work on microorganisms from deep trenches
shows they are indeed different. The chemistry derived from
these, though limited in scope, shows high novelty.
Why study these diseases? In the case of antibiotics, the
pipeline for new antibiotics has paradoxically experienced a
long-term decline. Antibiotics are being developed, but not
ones targeting the most urgent needs, and not in the diverse
portfolio required to combat the rise of bacterial resistance.
No new class of antibiotics has been discovered since 1987
but a new infection emerges on an almost yearly basis
(Be´rdy, 2012). Diseases such as MRSA have become major
problems in hospitals, evolving to become resistant to the
limited number of antibiotics available. Hence the urgent
need to discover new antimicrobials in many EU drug discov-
ery projects (e.g. MicoB3, MACUMBA and others).
PharmaSea is also looking for (a) anti-inﬂammatory com-
pounds targeting diseases such as atherosclerosis and
Alzheimer’s, and (b) neuroactive compounds targeting CNS dis-
orders such as epilepsy. An estimated 44 million people world-
wide suffer fromdementia and Alzheimer’s disease is the biggest
cause, but the available treatments are inadequate and only
improve some of the symptoms. There are also an estimated
70 million epilepsy patients worldwide, and 30% of these are
pharmacoresistant, creating an urgent need for novel anti-
epileptic drugs. With the growing and ageing population world-
wide, and without the effective cures, it is anticipated that the
number of patients with these diseases will increase dramatically
in the coming decades. To avert the worst of this crisis, and to
secure a sustainable source of more effective drugs, bottlenecks
in the drug discovery process must be overcome.
Having its main focus on the discovery of new compounds
bioactive in the above-mentioned therapeutic areas,
PharmaSea also aims to overcome some of the bottlenecks
currently found in the biodiscovery process, leading to (1)
improvements in the quality of marine resources available
for biotechnological exploitation, (2) to shorten time to
market, and (3) develop sustainable modes of supply of raw
materials for industry. The ﬁrst challenge is being targeted
by exploring the biotechnological potential of microorganisms
such as bacteria, fungi and microalgae to overcome problems
associated with supply of bioactives since microorganisms are
generally more amenable to mass cultivation in large-scale
enclosed bioreactors, as already demonstrated for the biofuel
and nutritional supplement industries. The two last challenges
centre on enabling activities to clarify legal aspects to facilitate
access to marine resources, their sustainable use, and their
secure exploitation; and second, to create an improved frame-
work for accessing marine biotechnology data and research
materials. To achieve these goals, PharmaSea brings together
complementary and world-leading experts, integrating
biology, genomics, natural product chemistry, bioactivity
testing, industrial bioprocessing, legal aspects, market analysis
and knowledge exchange.
Furthermore, to address the issue of inaccessible biodiver-
sity, innovative technologies are being developed to allow
more frequent and cost efﬁcient retrieval of, for example,
deep-sea microbes. Selection of new habitats such as the
deep-sea has increased the number of novel species, which
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are obtained using selective isolation techniques. Phylogenetic
and genomic strategies have further guided selection of strains
based on biosynthetic capacity. These high-quality strains are
being cultured in varying conditions to elicit their biosynthetic
repertoire while those recalcitrant to culture are being
exploited using a metagenomic approach.
To date the PharmaSea project has cultivated and extracted
more than 1400 microbial strains from extreme marine envir-
onments, with the majority being fungi and actinobacteria
(Figure 3A). These have been cultivated in a number of differ-
ent media with different stresses applied to elicit production of
secondary metabolites. The strains investigated so far have
yielded a total of over 15,000 extracts and fractions which
have been subjected to a broad range of antimicrobial and
central nervous system disease assays (Figure 3B). The patho-
genic bacteria and fungi used in this assay panel include
Gram-positive (methicillin resistant Staphylococcus aureus,
MRSA) and Gram-negative bacteria (Pseudomonas aeruginosa,
Acinetobacter baumannii and Escherichia coli), fungi (Candida
albicans and Aspergillus fumigatus) (Audoin et al., 2013), and
two surrogate (avirulent) strains of Mycobacterium, namely
Mycobacterium tuberculosis H37Ra and Mycobacterium bovis
BCG. Additionally, all samples are also tested in an assay to
detect compounds potentiating the effect of the b-lactam anti-
biotic imipenem against P. aeruginosa, with extracts and frac-
tions tested against the pathogen in the presence or absence
of a sub-lethal concentration of the antibiotic. Assay incubation
times range from overnight in the antibacterial and antifungal
assays to 7-day incubations in assays against Mycobacterium
strains. In order to reduce the high number of hits in anti-
infective screens (Figure 3C) we are using a state of the art
LC/MS based dereplication approach. This immediately
excludes extracts containing known antibiotics and identiﬁes
those containing chemical novelty (Lacret et al., 2015). These
extracts are being subjected to further work to identify and
chemically characterize the active components.
Neuroactive extracts and fractions, for potential applications
to treat epilepsy and other CNS disorders, are tested using high-
throughput behavioural ﬁngerprinting and seizure assays in zeb-
raﬁsh larvae (e.g. VanHook, 2010; Cunliffe, 2015). Zebraﬁsh-
based behavioural ﬁngerprinting provides initial data as to the
putative mechanism of action of neuroactive molecules, and pro-
vides preliminary mechanism of action information for isolated
compounds, thereby helping to rapidly prioritize those with
novel mechanisms of action. In addition to anti-infective and
neuroactivity screens, anti-inﬂammatory and toxicity screens
are also carried out (Figure 3C). Figure 3D further shows the dif-
ferent assays used to evaluate the neuroactivity and anti-
inﬂammatory activity in the primary screen. It also shows the per-
centage of screening events performed to evaluate toxicity.
Simultaneous with the screening process, extracts are being
dereplicated at an early stage through the use of innovative che-
mometric methods. Extracts identiﬁed as validated actives in a
selected assay and which are non-toxic have also been evaluated
for their likelihood of containing novel compounds using che-
mometrics. Extracts identiﬁed using this protocol are puriﬁed
Fig. 3. Pie diagrams showing composition of the PharmaSea strain library (A) and extract library (B) for different groups of microorganisms. Total number of
anti-infective (C) and other (D) screening events up to June 2015.
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using targeted chromatographic techniques followed by pio-
neering compound dereplication strategies leading directly
into an accelerated workﬂow for full structure determination.
This is only possible through the involvement of one of the
world’s largest chemical databases and a chemical software
company, which has enabled the prediction of NMR and MS
spectra of most known marine and microbial natural products.
The global aim of PharmaSea is to produce two compounds
at a larger scale and advance them to pre-clinical evaluation.
Assay cascades are used as the ﬁrst step in a protocol to decide
which extracts to progress. Those showing good in vitro
potency, low toxicity and high probability of containing novel
compounds are taken forward to isolate the active compounds
as potential pharmaceutical candidates. Scale-up fermentation
in saline media is being used to generate adequate amounts of
target compounds. In addition, identiﬁed novel gene clusters
are being expressed in heterologous hosts. Extracts that show
interesting bioactivity e.g. low cytotoxicity and/or dual activity
from cell based screens e.g. anti-inﬂammatory and antioxidant,
will be subjected to additional screens to identify their potential
value as novel applications of marine natural products in per-
sonal care and nutrition as part of follow-on projects.
Bioactive compounds will be developed by SME partners
and with larger pharmaceutical companies, if appropriate. To
address relevant challenges in marine biodiscovery related to
policy and legal issues, PharmaSea has brought together practi-
tioners, legal experts, policy advisors/makers and other stake-
holders, focusing on the feasibility of harmonizing, aligning
and complementing current legal frameworks with recommen-
dations and ready to use solutions tailored to marine biodiscov-
ery (Lallier et al., 2014). This work will also generate a toolkit to
enable users to explore the existing difﬁculties of access and
beneﬁt sharing under different legal regimes and ﬁnd practical
guidance to secure access to marine genetic resources. Uptake
of products derived from marine bioresources will be improved
via a number of mechanisms making PharmaSea data/IP avail-
able under licence to interested end-users.
CONCLUD ING REMARKS
Discovery of natural bioactive molecules is, of course, only the
ﬁrst step in the biodiscovery pipeline. The hardest challenge is
turning these products into useful medicines because the costs
of bringing a new drug to market from discovery through clin-
ical trials to approval is currently $2558 million, according to a
new study by the Tufts Center for the Study of Drug
Development (http://csdd.tufts.edu/news/complete_story/
pr_tufts_csdd_2014_cost_study), costs that have more than
doubled in the last decade. The same Center also reports that
only 11.8% of drug compounds entering clinical testing are
eventually approved. Another major challenge is to reduce the
time to market, which is currently 10 years. Both factors are
discouraging pharmaceutical industries which also have to
cope with the fact that the marine environment is largely unex-
plored and does not offer certainty on the successful outcome of
investment. This is complicated by the large investment required
to organize oceanographic cruises and to sample in extreme
environments where chances of ﬁnding greater biodiversity
are higher. A further complication regards the legal aspects to
access and utilization of marine natural products (or genetic
resources) that have been formalized in a series of agreements
such as the Convention on Biological Diversity (CBD) and its
Nagoya Protocol on Access to Genetic Resources and the Fair
and Equitable Sharing of Beneﬁts Arising from their
Utilization (Nagoya Protocol, as well as the United Nations
Convention on the Law of the Sea (UNCLOS)). The Nagoya
protocol, expected to enter into force in 2015, will enable stake-
holders to better understand and comply with national access
and beneﬁt-sharing procedures. For example, when the
genetic material is accessed from an ‘ex situ’ collection such as
a biorepository then the access provision of the CBD and the
Nagoya protocol apply. If the genetic material is collected ‘in
situ’ during an expedition then UNCLOS provisions will also
apply (for further details on legal framework to access and
beneﬁt sharing see Lallier et al., 2014 and references therein).
Notwithstanding these difﬁculties, the discovery of new ocean
medicines is one of the most promising new directions of
marine science today. Novel initiatives including partnering
between governmental organizations and industry are being
developed tomeet the difﬁculties incurred in the drug discovery
pipeline. Projects such as PharmaSea represent an example of
such a partnership, as will future programmes being organized
within the framework of Horizon 2020.
The oceans can therefore provide us with many invaluable
beneﬁts and services, including some of the medicines we use to
cure human disease. However, the oceans are under serious
threat due to pollution and global change. We even contaminate
the ocean and its inhabitants by dumping chemicals from drug
manufacturing into the world’s waterways, polluting villages,
cities and aquatic ecosystems around the world, eventually con-
taminating the ﬁshwe eat (Larsson, 2014) and the very organisms
that could provide us with new cures for human diseases in the
future. With the global population projected to increase from 7
to 9 billion people in the next few decades, there is an urgent
need to secure a healthy and productive global ocean. A healthier
ocean that is better managed could provide more food and
employment. It could also ensure that the beneﬁts from the
exploitation of ocean resources can be sustainably managed
and equitably shared. Knowledge on the effects of pollution
and global change onmarine organisms are limited and still rela-
tively unexplored, leaving critical knowledge gaps for those
seeking to develop effective policies for sustainable use of
marine resources and environmental and human health protec-
tion (EuropeanMarine Board, 2013). A better understanding of
the potential health beneﬁts from marine organisms, the com-
pounds they produce, and the environmental conditions affect-
ing their production will allow for the better management and
sustainable development of these valuable marine resources in
the future. By pursuing the medical promises hidden within
the ocean, while also managing the dangers to human health
found in this new frontier, ocean scientists can make a major
contribution to improving human health in the 21st century
and beyond.
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